Former Merck staffer charged in insider trading case

The latest pharma company to wind up in the middle of insider trading charges? Merck. A former employee at the drug giant has been charged after allegedly tipping off a former classmate about potential deals that scored him $683,000.

The SEC and federal prosecutors earlier this week filed a civil and criminal complaint against 32-year-old Zachary Zwerko, a senior finance analyst in the company's financial evaluation and analysis group, who worked at Merck ($MRK) until July, the Boston Globe reports. According to court documents seen by the paper, Zwerko shared info from confidential files about Merck's acquisition targets with his friend, a trader, who was not charged in this case.

From there, the friend went on to trade based on Zwerko's tips, making moves on a future Merck buyout of Idenix ($IDIX) as well as Ardea Biosciences and ViroPharma--both considered potential acquisitions at the time and both that were bid on by other companies, Reuters reports. The resulting charge? One count of conspiracy to commit securities fraud.

As a Merck spokeswoman told the news service, the company is cooperating with the SEC on the case. As for Zwerko, he's required to appear in a New York court this week after being released on a $1 million bond.

M&A, which has abounded in the pharma industry as of late, also set the stage for another recent insider trading charge--this one pinned on a former Bristol-Myers Squibb ($BMY) exec. Last October, Robert Ramnarine landed behind bars for a year and a day after pleading guilty to profiting off private information about BMS' buyout of diabetes-drug specialist Amylin Pharmaceuticals.

- see the Boston Globe story
- get more from Reuters

Special Report: The top 10 pharma companies by 2013 revenue - Merck | Pharma's top 10 M&A deals of 2013

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.